Vegard S.
- Country
- Norway
- Department
- Department of Infectious Diseases
Research Overview
- European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct)
- Evaluation of Antibiotic Discontinuation in Adult Patients with Viral Respiratory Tract Infections: A Randomized Controlled Trial
- Evaluation of Gentamicin and Narrow-Spectrum Beta-Lactams Versus Broad-Spectrum Beta-Lactams in Empirical Treatment of Suspected Community-Acquired Sepsis
Data & Insights
Has run more than one trial at 9 of 73 partner sites.
Specializations
Infectious Disease Research
This investigator specializes in the study of SARS-CoV-2 infection and its clinical manifestations, with particular emphasis on treatment approaches for hospitalized patients with varying disease severity.
- Moderate COVID-19 Management
- Severe COVID-19 Treatment
- Critical Care Medicine
Their research encompasses therapeutic interventions for both moderate and severe disease presentations.
Immunocompromised Patient Care
The investigator focuses on developing treatment strategies for immunocompromised patients affected by severe viral infections, particularly in hospital settings.
- Targeted Therapeutic Approaches
- Hospital-Based Treatment
- Disease Progression Management
Their work addresses the specific needs of vulnerable patient populations requiring specialized therapeutic interventions.
Adaptive Platform Studies
The investigator engages in emerging infection research through adaptive platform trials, focusing on pandemic response strategies and therapeutic evaluations.
- Platform Trial Design
- Pandemic Response Research
- Treatment Protocol Development
Their research contributes to the development of flexible clinical trial frameworks for emerging infections.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.